علاج التخثر الأساسي في المرضى فوق سن 60 عامًا مع JAK2 طبيعي النمط وبدون تاريخ تجلطي

DOI: 10.1002/ajh.27216

Figure 5 outlines our general treatment approach in ET, which starts with thrombosis risk stratification: very low (age ≤60 years, no thrombosis history, JAK2 wild-type), low (same as very low but JAK2 mutation present), intermediate (age >60 years, no thrombosis history, JAK2 wild-type), and high (thrombosis history present or age >60 years with JAK2 mutation).

Twice-daily aspirin is also our current treatment choice for intermediate-risk disease, but combination of a cytoreductive drug with once-daily aspirin is a reasonable alternative in intermediate-risk patients with CV risk factors (Figure 5).

Low-dose aspirin therapy has also been shown to be effective in alleviating vasomotor (microvascular) disturbances associated with ET or PV.